Search

Your search keyword '"Angelico, M."' showing total 1,268 results

Search Constraints

Start Over You searched for: Author "Angelico, M." Remove constraint Author: "Angelico, M."
1,268 results on '"Angelico, M."'

Search Results

101. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

102. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C

103. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

104. Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF)

105. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

106. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

107. Natural HCV resistance is common in Italy and differently associated to genotypes

108. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

109. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease

110. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

111. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

112. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens

113. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

114. An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets

115. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?

116. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease

117. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

118. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

119. The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification

120. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

121. Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study

122. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus-infected patients treated with recommended regimens

123. Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA

124. Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain

125. THE UN-SUSTAINABLE MATCH IN HCV LIVER TRANSPLANT PATIENTS

126. Worse Graft Survival in HCV-Infected Transplanted Females Receiving a Male Donor Graft. The Liver Match Study

127. Short-Term, Low-Dose Use of Tolvaptan as a Bridge Therapy to Expedite Liver Transplant for Severe Hyponatremic, Cirrhotic Patients With High Model for End-Stage Liver Disease Scores

128. WWW.D-MELD.COM THE PROGNOSTIC CALCULATOR TO BALANCE DONOR AND RECIPIENT LIVER TRANSPLANT FACTORS USING D-MELD AND COVARIATES

129. Prediction of Outcome after Liver Transplantation by D-MELD. Stratification of Graft Survival According to Donor Recipient Match in the Italian Multicenter Study

130. D-MELD, a Powerful Predictor of Graft Survival after Liver Transplantation. Long-Term Results of a Multicenter Italian Study

131. THE BENEFIT OF ANTIVIRAL THERAPY ON FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT): AN ITALIAN MULTICENTER STUDY

132. GENOTYPE 2 AND 3 RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

133. FIBROSIS PROGRESSION AFTER ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

134. ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION: THE IMPACT ON FIBROSIS PROGRESSION

135. Worse Graft Survival in HCV-Infected Transplanted Females Receiving a Male Donor Graft. The Liver Match Study

136. The Un-sustainable Match In Hcv Liver Transplant Patients

137. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study

138. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients

139. Www.d-meld.com the Prognostic Calculator To Balance Donor and Recipient Liver Transplant Factors Using D-meld and Covariates

140. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

141. Prediction of Outcome after Liver Transplantation by D-MELD. Stratification of Graft Survival According to Donor Recipient Match in the Italian Multicenter Study

142. D-MELD, a Powerful Predictor of Graft Survival after Liver Transplantation. Long-Term Results of a Multicenter Italian Study

143. FIBROSIS PROGRESSION AFTER ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

144. The Benefit of Antiviral Therapy On Fibrosis Progression Due To Hcv Recurrence After Liver Transplantation (lt): An Italian Multicenter Study

145. GENOTYPE 2 AND 3 RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

146. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

147. Expert Consensus Conference - The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005

148. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

149. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

150. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?

Catalog

Books, media, physical & digital resources